abstract |
The present invention discloses compounds that are highly isozyme selective, protein kinase C beta-1 and beta-2 isozyme inhibitors. These compounds are 3,4-di-[3'(1'-substituted)-indolyl]-1H-pyrrol-2,5-diones, which can be more commonly described as 3,4-bis(3'-indolyl) maleimides. Also, as isozyme selective inhibitors of the beta-1 and beta-2 isozymes, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of these isozymes. |